A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB study
Authors
Keywords
-
Journal
BRAIN BEHAVIOR AND IMMUNITY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-11-03
DOI
10.1016/j.bbi.2023.10.025
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Serum immune markers and transition to psychosis in individuals at clinical high risk
- (2023) Valeria Mondelli et al. BRAIN BEHAVIOR AND IMMUNITY
- Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial
- (2021) Maria Antonietta Nettis et al. NEUROPSYCHOPHARMACOLOGY
- Doxycycline exposure during adolescence and future risk of non-affective psychosis and bipolar disorder: a total population cohort study
- (2021) Fredrik Upmark et al. Translational Psychiatry
- Meta-analysis of the Glial Marker TSPO in Psychosis Revisited: Reconciling Inconclusive Findings of Patient–Control Differences
- (2020) Pontus Plavén-Sigray et al. BIOLOGICAL PSYCHIATRY
- Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning
- (2019) Carl M. Sellgren et al. NATURE NEUROSCIENCE
- Meta-analysis of cytokine and C-reactive protein levels in high-risk psychosis
- (2019) Sora Park et al. SCHIZOPHRENIA RESEARCH
- Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial
- (2019) Maximus Berger et al. Frontiers in Psychiatry
- The NEURAPRO biomarker analysis: long-chain omega-3 fatty acids improve 6-month and 12-month outcomes in youth at ultra-high risk for psychosis
- (2019) G Paul Amminger et al. BIOLOGICAL PSYCHIATRY
- Efficacy of omega-3 PUFAs in depression: A meta-analysis
- (2019) Yuhua Liao et al. Translational Psychiatry
- Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis
- (2019) Ayedh Alqarni et al. SCHIZOPHRENIA RESEARCH
- Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis
- (2018) Cathy Davies et al. World Psychiatry
- A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone
- (2018) Delbert G. Robinson et al. SCHIZOPHRENIA RESEARCH
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Meta-analysis of Immune Parameters, Variability, and Assessment of Modal Distribution in Psychosis and Test of the Immune Subgroup Hypothesis
- (2018) Toby Pillinger et al. SCHIZOPHRENIA BULLETIN
- The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial
- (2018) Mark Weiser et al. SCHIZOPHRENIA RESEARCH
- Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial
- (2017) Muhammad I Husain et al. JOURNAL OF PSYCHOPHARMACOLOGY
- 23. Omega-3 Fatty Acid Versus Placebo in a Clinical High-Risk Sample From the North American Prodrome Longitudinal Studies (NAPLS) Consortium
- (2017) Kristin Cadenhead et al. SCHIZOPHRENIA BULLETIN
- The Clinical High-Risk State for Psychosis (CHR-P), Version II
- (2017) Paolo Fusar-Poli SCHIZOPHRENIA BULLETIN
- A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol
- (2017) Inti Qurashi et al. Trials
- Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders
- (2017) Patrick D. McGorry et al. JAMA Psychiatry
- Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression
- (2016) Brian Hallahan et al. BRITISH JOURNAL OF PSYCHIATRY
- Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods
- (2015) Tomasz Pawełczyk et al. BMC Psychiatry
- A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia
- (2013) H Bentsen et al. Translational Psychiatry
- Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment
- (2012) Imran B Chaudhry et al. JOURNAL OF PSYCHOPHARMACOLOGY
- The Validity of the 16-Item Version of the Prodromal Questionnaire (PQ-16) to Screen for Ultra High Risk of Developing Psychosis in the General Help-Seeking Population
- (2012) H. K. Ising et al. SCHIZOPHRENIA BULLETIN
- Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders
- (2010) G. Paul Amminger et al. ARCHIVES OF GENERAL PSYCHIATRY
- Prediction of Psychosis in Youth at High Clinical Risk
- (2008) Tyrone D. Cannon et al. ARCHIVES OF GENERAL PSYCHIATRY
- Microglia Activation in Recent-Onset Schizophrenia: A Quantitative (R)-[11C]PK11195 Positron Emission Tomography Study
- (2008) Bart N. van Berckel et al. BIOLOGICAL PSYCHIATRY
- Minocycline as Adjunctive Therapy for Schizophrenia
- (2008) Tsuyoshi Miyaoka et al. CLINICAL NEUROPHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now